Citation: samayoa j.
, et al.
Echocardiographic assessment of melody versus sapien valves following transcatheter pulmonary valve replacement.
Jacc cardiovasc interv.
2022 jan 24;15(2):165-175.
Doi: 10.
1016/j.
Jcin.
2021.
11.
002.
Pmid: 35057987 earliest date of publish used for date of event.
Medtronic products referenced: melody (pma# p140017, product code: npv).
Earliest approved product used for product code and pma#.
No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.
Without return of the product no definitive conclusion can be made regarding the clinical observations.
If information is provided in the future, a supplemental report will be issued.
|
Medtronic received information via literature regarding the intermediate/mid-term performance of two competitor transcatheter pulmonary valves, based upon echocardiography.
All data were retrospectively collected from a single center between 2011 and 2020.
The study population included 328 pediatric and adult patients, with 202 of them implanted with medtronic melody bioprosthetic valves (predominantly male, mean age 14.
4 years, mean weight 49.
1 kg; unique device identifier numbers not provided).
Among all medtronic melody patients, adverse events included: two cases of endocarditis with high transvalvular gradients and pulmonary stenosis (ps), requiring surgical explantation and pulmonary valve replacement.
The timeline of endocarditis development was not reported within the article.
Based on the available information medtronic product may have been associated with the adverse events.
No further patient complications have been reported as a result of this event.
|